Candel Therapeutics to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Candel Therapeutics, Inc. (Nasdaq: CADL) announced the acceptance of an abstract for presentation at the ASCO Annual Meeting 2022, scheduled for June 3-7 at McCormick Place, Chicago. The abstract will present data from a phase 2 clinical trial on CAN-2409 and valacyclovir in combination with anti-PD-1/PD-L1 agents for treating stage III/IV NSCLC patients. Key details include:
- Abstract Title: First report of safety/tolerability and preliminary antitumor activity of CAN-2409
- Presenter: Charu Aggarwal
- Date: June 6, 2022
- Abstract Number: 9037
- None.
- None.
NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2022, which will be held in person from June 3 – 7, 2022, at the McCormick Place Convention Center in Chicago, Illinois. The presented data will detail clinical outcomes from Candel’s phase 2 clinical trial evaluating CAN-2409 and valacyclovir in combination with anti-PD-1 or PD-L1 agents in patients with stage III/IV NSCLC.
Presentation details:
- Abstract Title: First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC
- Presenter: Charu Aggarwal, MD, MPH, Associate Professor of Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
- Session Date and Time: Monday, June 6, 2022, from 8:00 AM – 11:00 AM CDT
- Abstract Link: https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions
- Session Title: Lung Cancer – Non-Small Cell Metastatic
- Abstract Number: 9037
About Candel Therapeutics
Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neoantigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. The enLIGHTEN™ Discovery Platform is based on Candel’s HSV technology.
For more information about Candel, visit www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, include key data readout milestones; expectations regarding the therapeutic benefit of its programs; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, and strategic plans for the Company’s business and product candidates, and other risks identified in the Company’s SEC filings, including the Company’s Registration Statement on Form S-1, the Company’s Annual Report on Form 10-K filed on March 29, 2022, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Media Contact
Heidi Chokeir, PhD
Managing Director
Canale Communications
heidi.chokeir@canalecomm.com
619-203-5391
Investor Contact
Sylvia Wheeler
Principal
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
FAQ
What is the significance of Candel Therapeutics' presentation at ASCO 2022?
When will Candel Therapeutics present at the ASCO Annual Meeting 2022?
What is the focus of Candel's clinical trial presented at ASCO 2022?
Who will present the findings on CAN-2409 at ASCO 2022?
How can I find the abstract for Candel Therapeutics' presentation at ASCO 2022?
